Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone

Table 1 Randomized controlled trials (GEM combination vs GEM alone)

Studies	Intervention	Patients	OS (d)	6-mo survival (%)	1-yr survival (%)	6-mo TTP/PFS/TTF rate (%)	ORR (CR + PR) %	CBR	Jadad score
Scheithauer 2003[8]	Gem	42	246	59.4	37.2	24.6 (PFS)	6/42	10/30	3
	Gem + Capecitabine	41	285	67.7	31.8	36.9	7/41	15/31
Colucci 2002[9]	Gem	54	140	31.5	11	18 (TTP)	5/48	21/43	3
	Gem + DDP	53	210	47	11.3	28	14/45	20/38
Wang XY 2002[10]	Gem	20	-	81.3	31.3	-	1/16	14/16	3
	Gem + DDP	22	-	61.6	11.1	-	2/18	14/20
Gansauge 2002[11]	Gem	28	144	32	11	-	1/28	-	3
	Gem + NSC-631570	28	279	64	29	-	6/28	-
Berlin 2002[12]	Gem	162	162	42	15.5	32/160 (PFS)	9/162	-	3
	Gem + 5-FU	160	201	55	21.9	41/158	11/160	-
Bramhall 2002[13]	Gem + placebo	119	164	43	17	23 (TTF)	14/88	-	5
	Gem + marimastat	120	165.5	47	18	29	11/97	-
Cutsem 2004[14]	Gem + placebo	347	182	49	24	-	28/347	-	5
		341	193	53	27	-	20/341	-
Louvet 2005[15]	Gem	156	213	60.4	27.8	27.4 (PFS)	27/156	26.9	3
	Gem1 + Oxaliplatin	157	270	68	34.7	43	42/157	38.2
Reilly 2004[16]	Gem	174	186	51	21	27 (TTP)	9/127	-	3
	Gem + DX-8951f	175	201	54	23	39	12/147	-
Richards 2004[17]	Gem	282	189	50.9	20.1	27.6 (PFS)	20/220	-	3
	Gem + Pemetrexed	283	186	50.9	21.4	32.1	42/230	-
Li CP 2004[18]	Gem	25	138	20.3	13.6	11.8 (TTP)	3/25	9/25	3
	Gem + DDP	21	168	31.1	6.3	11.8	2/21	6/21
Reni 2004[19]	Gem	47	-	63.9	21.3	12.9 (PFS)	4/47	5/20	3
	Gem + 5-FU + DDP + EPI	52	-	64.6	38.5	37.4	20/52	15/23
Viret 2004[20]	Gem	41	201	58.3	25.1	10 (TTF)	2/41	-	3
	Gem + DDP	42	241	55.5	32.4	14	3/42	-
Rocha Lima 2004[21]	Gem	180	198	52.9	22	21.9 (TTP)	8/180	-	3
	Gem + Irinotecan	180	189	50.7	21	30.6	29/180	-
Costanzo 2001[22]	Gem	49	217	59	14.5	-	4/48	-	3
	Gem + 5-FU	44	210	59	23.3	-	5/43	-
Heinemann 2003[23]	Gem	97	180	48.6	22.5	25.6 (TTP)	8/93	-	3
	Gem + DDP	95	228	59.4	27.5	39.3	10/92	-
Kulke 2004[24]	Gem2	45	-	24/45	-	-	-	-	3
	Gem + DDP	45	-	23/45	-	-	-	-
	Gem + Docetaxel	49	-	22/49	-	-	-	-
	Gem + Irinotecan	44	-	21/44	-	-	-	-
Richards 2002[25]	Gem + Placebo	88	213	62.9	20.4	25.9 (TTF)	5/63	-	5
	Gem + CI-994	86	191	60.8	18.5	16.7	1/61	-
Moore 2005[26]	Gem + Erlotinib	285	191	58	24	32 (PFS)	23/268	-	5
	Gem + placebo	284	177	49	17	25	21/262	-
Stathopoulos 2005[27]	Gem	70	195	50	21.82	-	7/70	-	3
	Gem + Irinotecan	60	192	60	24.29	-	9/60	-
Riess 2005[28]	Gem	236	186	53	20	30 (TTP)	17/236	-	3
	Gem + 5-FU/CF	230	175.5	49	20	29	11/230	-
Herrmann 2005[29]	Gem	157	219	62	27	42 (PFS)	12/1523	-	3
	Gem + Capecitabine	159	252	60	31	42	15/148	-

¹Gemcitabine 1 g/m² as a 100-min infusion;

²Gemcitabine 1500 mg/m² at a fixed dose rate of 10 mg/m² per minute;

³RECIST criteria.